Foghorn Therapeutics (NASDAQ:FHTX) and Praxis Precision Medicines (NASDAQ:PRAX) Head to Head Review

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) and Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Earnings & Valuation

This table compares Foghorn Therapeutics and Praxis Precision Medicines”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Foghorn Therapeutics $30.91 million 4.02 -$74.28 million $0.07 29.57
Praxis Precision Medicines $8.55 million 1,072.66 -$303.27 million ($12.80) -25.64

Foghorn Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

61.5% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Foghorn Therapeutics and Praxis Precision Medicines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foghorn Therapeutics 8.40% -13.46% 4.63%
Praxis Precision Medicines N/A -29.41% -28.19%

Volatility and Risk

Foghorn Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Foghorn Therapeutics and Praxis Precision Medicines, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics 1 6 4 0 2.27
Praxis Precision Medicines 2 1 16 3 2.91

Foghorn Therapeutics currently has a consensus price target of $6.14, indicating a potential upside of 196.76%. Praxis Precision Medicines has a consensus price target of $631.68, indicating a potential upside of 92.51%. Given Foghorn Therapeutics’ higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Praxis Precision Medicines.

Summary

Foghorn Therapeutics beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.

About Foghorn Therapeutics

(Get Free Report)

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.